Glucose Sensitive Insulin
Our latest work, in collaboration with Novo Nordisk and University of Bristol, as featured in Nature magazine.
This video is also available on YouTube
What is Glucose Sensitive Insulin and how were Ziylo/Carbometrics involved in this project?
Glucose-Sensitive Insulin (GSI), also known as glucose-responsive insulin (GRI), is potentially revolutionary drug concept that involves equipping insulin with a molecular 'dimmer switch'.
Regular insulin has the same effect (potency) regardless of the person's blood glucose. Glucose-sensitive insulin should be more active at high blood glucose, and less active at low blood glucose levels. This is safer and allows better control of the desired blood glucose level.
The 'dimmer switch' is built from Carbometrics' Glucose Binding Molecule (GBM) — a bespoke, super-selective synthetic molecule designed to bind only glucose. Here's how it works:
Since its inception following the acquisition of Ziylo by Novo Nordisk, Carbometrics has been instrumental in providing specialised expertise and synthetic support crucial to the development of GSI. Carbometrics offers a comprehensive package of services to prospective clients, leveraging our deep understanding of synthetic chemistry, optoelectronic and biomolecular design to innovate solutions in the medical and bioprocessing sectors. Our proven track record and collaborative approach makes Carbometrics a valuable partner in the development of novel therapeutic and diagnostic strategies. If you have a project you would like to discuss with us, please get in touch to find out how Carbometrics could help today.